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Blood-brain barrier dysfunction characterised by brain parenchymal extravasation of plas-
ma proteins may contribute to risk of neurodegenerative disorders, however the mecha-
nisms for increased capillary permeability are not understood. Increasing evidence
suggests vitamin D confers central nervous system benefits and there is increasing de-
mand for vitamin D supplementation. Vitamin D may influence the CNS via modulation of
capillary function, however such effects may be indirect as it has a central role in maintain-
ing calcium homeostasis, in concert with calcium regulatory hormones. This study utilised
an integrated approach and investigated the effects of vitamin D supplementation, parathy-
roid tissue ablation (PTX), or exogenous infusion of parathyroid hormone (PTH) on cerebral
capillary integrity. Parenchymal extravasation of immunoglobulin G (IgG) was used as a
marker of cerebral capillary permeability. In C57BL/6J mice and Sprague Dawley rats, die-
tary vitamin D was associated with exaggerated abundance of IgG within cerebral cortex
(CTX) and hippocampal formation (HPF). Vitamin D was also associated with increased
plasma ionised calcium (iCa) and decreased PTH. A response to dose was suggested and
parenchymal effects persisted for up to 24 weeks. Ablation of parathyroid glands increased
CTX- and HPF-IgG abundance concomitant with a reduction in plasma iCa. With the provi-
sion of PTH, iCa levels increased, however the PTH treated animals did not show in-
creased cerebral permeability. Vitamin D supplemented groups and rats with PTH-tissue
ablation showed modestly increased parenchymal abundance of glial-fibrillary acidic pro-
tein (GFAP), a marker of astroglial activation. PTH infusion attenuated GFAP abundance.
The findings suggest that vitamin D can compromise capillary integrity via a mechanism
that is independent of calcium homeostasis. The effects of exogenous vitamin D supple-
mentation on capillary function and in the context of prevention of vascular
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neurodegenerative conditions should be considered in the context of synergistic effects
with calcium modulating hormones.
Introduction
In primary neurodegenerative conditions such as vascular-dementia, Alzheimer’s disease, mul-
tiple sclerosis and epilepsy; and in secondary neurodegenerative disorders such as stroke, cere-
bral capillary function is impaired, resulting in inappropriate blood-to-brain parenchyme
protein trafficking, neurovascular inflammation and if persistently exaggerated, cellular apo-
ptosis [1, 2]. Consistent with a causal association of capillary dysfunction in some neurodegen-
erative disorders, there is an accumulating body of literature from clinical studies and in
animal models showing therapeutic benefit in disease progression if blood-brain barrier (BBB)
disturbances are corrected or attenuated [3, 4].
Epidemiological and experimental studies suggest that vitamin D generally has a protective
role in neurodegenerative disorders although the mechanism(s) for these purported benefits
are not clear [5–7]. Analyses of transcription factors and signaling pathways support the con-
tention that a key effect of vitamin D is via positive regulation of genes broadly involved in neu-
rovascular inflammation [8]. However, other mechanisms relevant to neurodegenerative
conditions may include modulation of p-glycoprotein expression; up-regulation of serotonin
synthesizing genes; protein oligomerization (such as beta-amyloid) and apoptosis [9–11].
Some reported positive downstream effects of vitamin D include restoration of capillary func-
tion in models of multiple sclerosis and cessation of disease progression; enhanced cognitive
performance in subjects with mild cognitive impairment; decreased risk for Alzheimer’s dis-
ease; and in some psychiatric disorders, an improvement in behavior [12–17].
A consequence of the perceived positive effects of vitamin D in reducing risk of neurodegen-
erative disorders has generated momentum in developed nations with aging populations, to
consider adopting policies that promote vitamin D supplementation. However, this is a conten-
tious issue, as robust physiological studies to investigate potential vitamin D toxicology are not
yet realized and the ‘optimal’ vitamin D level remains controversial [5–7]. Moreover, the effects
of vitamin D may be via regulation of calcium homeostasis, or the effect of calcium regulatory
hormones, rather than via direct effects of the vitamin per se. Presently, there is little evidence
to support the hypothesis that vitamin D at greater than ordinary physiological concentrations
is likely to be beneficial.
An equivocal function of vitamin D is to regulate calcium metabolism. In response to low
serum levels of ionised calcium (iCa), sensor cells within parathyroid tissue promote secretion
of parathyroid hormone (PTH), which rapidly stimulates the conversion of vitamin D to its
bioactive form 1,25-dihydroxyvitamin D3 (1,25(OH)2D3). Bioactive vitamin D and PTH will
synergistically increase plasma iCa via enhancing intestinal absorption of dietary calcium, in-
creasing osteoclast activity to liberate calcium and reducing renal calcium excretion. The provi-
sion of supplemental vitamin D progressively increases iCa and concomitantly suppress PTH
secretion. Clearly then, cerebral capillary effects of exogenous vitamin D supplementation can-
not be considered in isolation.
Calcium is pivotal to neuronal excitability and indeed the changes that underlie learning
and memory [18–20]. In addition, calcium ions are critical in maintaining the integrity of the
BBB [21, 22]. Several studies have implicated an association between elevated serum iCa and
global cognitive decline [23–25]. Moreover, at greater concentrations and when chronically
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exaggerated, serum iCa is positively correlated with cerebral white matter lesions, greater lesion
volume and induction of the apoptotic cascade [19, 26–29]. If iCa is central to the neurovascu-
lar effects of vitamin D, then by extension of the clinical observations, supplementation with vi-
tamin D would notionally be beneficial in subjects with hypocalcemia, but possibly harmful in
subjects with raised, or adequate levels of serum calcium. Tai et al reported that the influx of
iCa into the CNS is not regulated by a saturable mechanism that is sensitive to acute changes in
plasma concentration, but more likely to occur through passive diffusion [30]. The CNS would
therefore notionally be protected from rapid acute changes in iCa [31, 32]. However, chronic
heightened effects may be realized. The effects of iCa on capillary permeability and on neuro-
vascular inflammation per se, have not been directly investigated.
Several lines of evidence also suggest that PTH may directly affect neurovascular integrity
independent of vitamin D homeostasis. PTH has been shown to cross the BBB and an exagger-
ated level of PTH within CSF appears to cause neuronal degeneration due to cellular iCa over-
loading [33, 34]. In clinical studies, increased levels of PTH have been reported as an
independent risk factor of age-related cognitive decline [35, 36]. Furthermore, case-controlled
findings show improved cognitive performance in subjects with hyperparathyroidism follow-
ing parathyroid surgery [37, 38]. Therefore, it is possible that studies reporting detrimental ef-
fects of vitamin D deficiency may be a surrogate marker of PTH induced sequelae.
Whilst capillary integrity is considered pivotal to risk or progression of a range of neurode-
generative disorders, regulation of capillary function via the vitamin D-iCa-PTH axis is neither
established nor elucidated. However, delineation of the putative synergistic effects of vitamin
D-iCa-PTH on capillary integrity may be of significant therapeutic importance. To this effect,
this study adopted intervention models of dietary vitamin D supplementation; exogenous para-
thyroid hormone supplementation or parathyroid tissue ablation in two genetically unmanipu-
lated rodent models, to investigate capillary permeability and neurovascular inflammation
within CNS regions of interest that are relevant to learning and memory.
Materials and Methods
Animals and dietary/hormonal interventions
All animals were housed in accredited animal holding facilities in individual ventilated cages
with 12-h light/dark cycle, controlled air temperature (21°C) and air pressure (Curtin Animal
Holding Facility, Perth and Charles River Laboratories, Kent). All animals were given ad libi-
tum access to specified diets and water. Dietary protocols and surgical procedures described in
this study were approved by NHMRC accredited Curtin Animal Ethics Committee (approval
no. N34-10 [mice] and AEC_2011_30A [rats]) and Charles River UK Ethics Committee (proj-
ect Licence no. 70/7221), respectively. All surgical and endpoint protocols were performed
under strict anaesthetic protocols to minimize pain and stress.
Dietary Vitamin D (VD) supplementation
7-week-old female wild-type C57BL/6J mice and Sprague-Dawley rats were purchased from
Animal Resources Centre (Murdoch, W.A, Australia). Animals were randomly assigned in
groups of 8 to one of the following semi-purified A1N93G diets: Control 0.5% Calcium, 0.35%
phosphorus containing 1000 IU; 20,000IU; 40,000 IU; 80,000 IU or 120, 000 IU vitamin D3/kg
diet (Specialty Feeds, Glenn Forrest, W.A, Australia). Eight animals from each group were sac-
rificed at either 6, 12 or 24 weeks after commencement of dietary intervention. The approxi-
mate daily intake of VD per animal (international units) is listed in Table 1.
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Parathyroid Gland Ablation
Seven week-old female Sprague-Dawley rats (200–250g) were randomly assigned as control an-
imals or subjected to selective parathyroidectomy (PTX) (Charles River Laboratories, Kent,
UK). Briefly, rats were placed under general anaesthesia via isofluorane and with the aid of a
dissecting microscope; parathyroid glands were identified, dissected and ablated from the sur-
rounding tissue. The skin wounds were closed using wound clips. Thereafter, animals were
provided with 1.5% calcium lactate solution 3 days post-operation. Both control and PTX
groups were given ad libitum access to standard SDS-VRF-1 diet (Calcium 1% Phosphate
0.6%) manufactured by Special Diet Services, UK and sacrificed at either 12 or 24 weeks. Suc-
cessful parathyroid tissue ablation was confirmed by determining circulating serum PTH. The
PTX treatment group data is indicative of rats with a PTH concentration<65pg/ml. At 12
weeks and 24 weeks post surgery data is presented for 4-PTX and 7-PTX rats, respectively.
Eight controls were studied alongside each PTX treatment group, at 12 and 24 weeks.
Exogenous Parathyroid Hormone Infusion
Seven week-old female Sprague-Dawley rats were randomly allocated to either control or
PTH-infused groups. All animals were placed under general anaesthesia and Alzet mini osmot-
ic pumps (2ML) were implanted subcutaneously between the scapulae of each animal
(Charles River Laboratories, Kent, UK), containing either saline and 2% cysteine (control
group) or rat 1–34 PTH fragment diluted in isosmotic saline with 2% cysteine at a concentra-
tion of 0.332ug/hour/rat (Bachem Labs, Switzerland). Skin wounds were closed using wound
clips. All osmotic pumps were primed and filled under aseptic conditions. Animals were given
ad libitum access to standard SDS-VRF-1 diet (Special Diet Services, UK) and sacrificed at ei-
ther 6 (control n = 9; PTH- infused n = 8) or 12 weeks (control n = 8; PTH-infused n = 4).
Treatment at 24 weeks could not be investigated as this would have required subsequent re-
placement of the mini osmotic pumps, a procedure not permitted by the ethics protocols. Rats
with incomplete wound healing at one week post pump insertion were humanely euthanized
under general anaesthesia. As exogenous PTH cannot be detected by PTH assays, we like other
laboratories utilized serum measures of ionised calcium and total calcium as a surrogate mark-
er of efficacy. In addition residual osmotic pump reservoir volume and weight confirmed deliv-
ery of the vehicle buffer/hormone.
Sample collection and preparation
At each intervention endpoint, rats were anaesthetized with 75mg/kg ketamine and 10mg/kg
xylazine whilst mice were anaesthetized with pentobarbitone (45 mg/kg) followed by exsangui-
nation via cardiac puncture. An initial 100ul of fresh whole blood was collected into plain sy-
ringes for immediate analysis of blood ionised calcium whist the remaining sample was left to
Table 1. Daily intakes of vitamin D.
Study Vitamin D3 (VD) per kg of diet (IU) Control (1, 000) 20, 000 40, 000 80, 000 120, 000
Mice Daily intake of VD (IU/day) 2 40 80 160 240
Intake of VD/kg/day (IU) 100 2, 000 4, 000 10, 000 16, 000
Rats Daily intake of VD (IU/day) 15 300 600 1, 200 1, 800
Intake of VD/kg/day (IU) 75 1, 500 3, 000 6, 000 9, 000
The approximate international units (IU) of vitamin D consumed by Sprague-Dawley rats and C57BL6/J mice per respective treatment group are shown as
units consumed per day or daily units consumed per kilogram of weight.
doi:10.1371/journal.pone.0125504.t001
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clot at room temperature for 30 minutes and centrifuged for serum extraction. Thereafter, sam-
ples were aliquoted and stored at -80°C until further analysis. Brain specimens were carefully
extracted and fixed in 4% paraformaldehyde (w/v in PBS, pH 7.2) for 24h, followed by cryopro-
tection with 20% sucrose for 72 h at 4°C. The brain specimens were then frozen in dry ice/iso-
pentane and stored at -80°C.
Cerebral Extravasation of Immunoglobulin G
The integrity of cerebral capillaries was assessed by measuring cerebral perivascular extravasa-
tion of the plasma protein immunoglobulin G (IgG), a marker of unspecific blood-to-brain
leakage of plasma proteins and macromolecules by 3-dimensional (3-D) semi-quantitative
immunomicroscopy, using methods as previously described, with minor modifications [39].
Briefly, 20μm brain cryosections were blocked with 10% goat serum in PBS for 30 min and
thereafter incubated with polyclonal goat anti-mouse IgG1 or goat anti-rat IgG1 antibodies
conjugated with Alexa 488 fluorochrome (1:100; Invitrogen, USA) at 4°C for 20 h. Nuclear
counterstains were performed for detection of cerebrovascular endothelial cells and the sec-
tions were mounted with anti-fade mounting medium. Negative controls were included with
all the experiments, which included the replacement of the primary antibody with either buffer
or an irrelevant serum. No fluorescent staining was observed in any of the negative controls.
Representative 3-D immunofluorescent micrographs were captured with AxioVert 200M
(Carl-Zeiss, Germany) coupled with an mRM digital camera and ApoTome optical sectioning
system. Each 3-D image was captured at a magnification of x200 (Plan-Neofluar 20x objective
lens) and consisted of at least 12 2-dimensional Z- stack images with a 1.225μm axial distance
optimized by Nyquist overlap theory. For each region of interest in the brain, a minimum of
10–30 3-D images was randomly captured from the cortex or hippocampal formation per ani-
mal. Capillary vessel fluorescence was excluded based on conservative threshold exclusion set-
tings and confirmed manually for each image processed as previously indicated [4, 39, 40],
avoiding confounders associated with extensive and incomplete perfusion with wash-out buff-
ers. All 3-D images were used for the subsequent quantitative analysis. The voxel intensity of
the fluorescent dye was calculated with Volocity 6.1 3-D image analysis software (PerkinElmer,
UK) and expressed per volume unit. The average of the total fluorescent intensities of all the
images in cortex and hippocampal formation regions were calculated within each animal and
thereafter compared between each of the treatment groups.
Immunofluorescent Analysis of Cerebral Inflammation
Similar to cerebral IgG immunomicroscopy, the cortex and hippocampal expression of glial
fibrillary acidic protein (GFAP) was determined as a surrogate marker for astrocyte activation
by utilizing immunodetection techniques as described previously [39, 41]. 20um brain cryosec-
tions were blocked with 10% goat serum and incubated with polyclonal rabbit anti-mouse
GFAP (1:200; Abcam, UK) for 20 h at 4°C. Polyclonal goat anti-rabbit IgG conjugated with
Alexa488 (1:200) was then applied to the sections for 2h at RT followed by DAPI nuclear coun-
terstain. Slides were mounted with anti-fade medium. Negative controls were run with every
experiment, which included the replacement of the primary antibody with either buffer or an
irrelevant serum. No fluorescent staining was observed for control tissues with the indicated
capture settings.
Biochemistry Analyses
Blood Ionised Calcium. Serum ionised calcium levels were measured to determine the
calcemic status of each animal. Whole blood was collected via cardiac puncture into non-
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coagulated syringes and immediately analysed with a hand-held VetScan iSTAT analyser and
CG8+ blood gas cartridges (Abbott Point of Care, Australia) in accordance with the manufac-
turer’s instructions. Appropriate aqueous controls were run at every endpoint.
Serum Total Calcium and Inorganic Phosphate. Serum total calcium and phosphate
were analysed by quantitative colorimetric assays by QuantiChrom Calcium and Phosphate
Assay kits, respectively, according to manufacturer instructions (BioAssay Systems, CA).
Serum Parathyroid Hormone. Serum PTH was measured with ELISA kits specific for the
detection of intact rat PTH 1–84 molecule (Immutopics Rat Intact PTH ELISA, San Clemente,
CA). The kit is supplied with prepared standards and two control sera and has a sensitivity of
1.6pg/ml and range to 3000pg/ml for serum or plasma. Intra-assay precision of<2.4% and
inter-assay variability of<6.0%. Reported values of PTH in rats have been reported between
40–400pg/ml [42–44]. In this study, serum was collected under identical conditions and PTH
determined on the same day for all treatment groups indicated.
Statistical Analysis
For quantitative immunomicroscopy, a minimum of 10 and up to 30 3-D images was captured
from each mouse and rat per region of interest, respectively. In total over 800 (mice) and 4000
(rat) 2-D images were taken per group. All raw data was log transformed and the arithmetic
mean was used as a measure of central tendency. Thereafter, all statistical analyses were done
with non-parametric statistics by one-way analysis of variance (ANOVA) analyses followed by
Tukey’s post hoc tests. Pearson’s correlation analysis was used to determine the association be-
tween parenchymal expression of IgG and specified plasma biomarkers. Data was considered
to be statistical significant where p value<0.05. Unless otherwise stated, all data are expressed
as mean +/ SEM. Statistical analyses were performed with IBM SPSS Version 22 (SPSS Inc.,
Chicago, USA).
Results
Parenchymal abundance of IgG was used to assess cerebral capillary permeability in wild-type
mice and rats maintained on diets supplemented with vitamin D. Fig 1 depicts the abundance
of IgG within cortex (CTX) and hippocampal formation (HPF) for the respective treatment
groups. The findings show a strong positive association between parenchymal IgG within CTX
and HPF and the dose of exogenous vitamin D provided. However, subtle differences in re-
sponse to vitamin D supplementation were observed between Sprague-Dawley rats and
C57BL/6J mice. Abundance of IgG within both CTX and HPF were markedly elevated within 6
weeks of treatment in rats consuming chow containing 80,000 IU VD/kg of diet, whereas the
treatment effect was not seen in mice until approximately 12 weeks of feeding. Thereafter, both
species showed stabilization in the abundance of parenchymal IgG, with persistently exaggerat-
ed amounts relative to control groups at 24 weeks of feeding, but comparable to vitamin D sup-
plemented animals at 12 weeks of feeding.
Greater dosages of vitamin D in rats were required to increase serum iCa above controls
compared to mice, however this may have reflected the markedly lower baseline values in con-
trol mice compared relative to control rats (Fig 2). Similarly, serum total Ca was progressively
increased and phosphate decreased respectively in mice, whereas little change in rats was indi-
cated at equivalent treatment dosages of vitamin D. A duration-of-treatment effect for the con-
centration of iCa, serum total calcium and phosphate is indicated in Fig 3. Vitamin D provided
at 80,000IU VD/kg significantly increased bioactive iCa, compared to control group in mice
within 6 weeks of treatment. However, effects were significant at 12 weeks for both species.
Thereafter, stabilization was indicated for the duration of treatment (up to 24 weeks). In mice,
Vitamin D Modulation of Cerebral Capillary Function
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Fig 1. Cerebral Capillary Integrity.Cerebral capillary vessel integrity was assessed using 3-dimensional semi-quantitative fluorescent immunomicroscopy
by measurement of parenchymal extravasation of plasmamacromolecule IgG in the cerebral cortex (cortex) and hippocampal formation (hippocampus) of
wild-type rats (A) and mice (B) supplemented with units of dietary vitamin D (VD) as indicated and measured in voxels per volume unit. The bar graphs
illustrate a strong dosage effect of vitamin D concentration and abundance of cerebral IgG in the cortex and hippocampal formation in both species; statistical
significance is denoted by different letters (p<0.05; n = 8; one way ANOVA followed by Tukey’s post hoc analysis). The bottom graphs demonstrate duration-
Vitamin D Modulation of Cerebral Capillary Function
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total calcium was also exaggerated compared to controls, but there was no difference in total
Ca in rats. Serum levels of phosphate essentially remained the same for the duration of treat-
ment for both species studied.
The effect of dietary vitamin D supplementation on circulating PTH concentration in rats is
provided in Fig 4. A marked dose response is indicated with serum PTH levels significantly at-
tenuated as a consequence of vitamin D supplementation. Marked suppression of PTH was evi-
dent within six weeks of intervention and persistent for the treatment duration of 24 weeks in
animals kept on exogenous vitamin D of 80, 000 IU VD/kg. The reported concentration of
PTH in rats reported over several decades is variable, indicative of different methods of immu-
nodetection [45, 46]. Nonetheless, vitamin D treatment effects on serum/plasma PTH concen-
tration are as in this study consistently substantive.
The effects of chronically suppressed serum PTH on capillary permeability without the con-
founder of dietary supplementation of vitamin D, was explored in other experimental groups,
that is in rats with surgical ablation of parathyroid tissue. Fig 5 shows that the parenchymal ex-
pression of IgG within CTX and HPF 12 weeks post parathyroidectomy was over 2-fold greater
compared to control animals. These effects persisted but were not significantly amplified fur-
ther when investigated at 24 weeks of intervention. Increased capillary permeability occurred
in PTH ablated rats concomitant with a reduction in iCa and to a lesser extent, total Ca. The
latter is a contraindication compared to the vitamin D intervention experiments, where in-
creased capillary permeability occurred concomitant with elevated iCa. We note that the serum
PTH concentration in control rats for PTH ablation (Fig 5) indicated a lower PTH concentra-
tion than in control rats for vitamin D intervention (Fig 4), despite identical serum preparation
and measures of PTH being done for all groups simultaneously. With a coefficient of variation
for this assay of less than 3%, our interpretation for differences in the concentration of PTH be-
tween control groups is the possibility of strain differences in rats hosted at two sites (Charles
River, UK for PTH interventions and vitamin D treated groups hosted at Curtin University,
Western Australia). Nonetheless, irrespective of this observed difference between the two con-
trol group PTH measures, comparison of treatment versus respective control is a valid
comparison.
Exogenous provision of PTH via the placement of mini-osmotic pumps predictably in-
creased serum iCa and total Ca. However, consistent with the findings in parathyroidecomized
rats, there was no suggestion that capillary permeability had been compromised as a conse-
quence of heightened serum iCa. Rather, parenchymal abundance of IgG within CTX and HPF
were comparable between rats given PTH and sham operated control rats hosting osmotic
pumps filled only with saline.
Table 2 depicts correlation analysis of cerebral capillary permeability with vitamin D, iCa,
total Ca, PTH and phosphate for all vitamin D supplemented and parathyroid-intervention ex-
perimental groups. The vitamin D studies in rats and mice suggest that provision of vitamin D
and the serum concentration of iCa are strongly associated with increased capillary permeability
within CTX and HPF. In addition, the vitamin D supplementation studies also show a marked
negative correlation between capillary permeability and the serum concentration of PTH. How-
ever, the PTH intervention experiments do not support the contention that the positive
of-treatment effects in both rodent species fed either control (open square/dotted lines) or diets enriched with 80, 000 IU VD/kg (black circles/solid lines) for 6,
12 and 24 weeks. Different letters show p<0.05 for duration effects within each group (n = 8) whilst an asterisk show statistically significant different dietary
effects between control group and its’ relevant treatment group at each time point (p<0.05; n = 8; one-way ANOVA followed by Tukey’s post hoc analysis).
Data is shown as mean ± SEM. Representative 2-dimensional extended-focus fluorescent immunomicrographs (magnification x 200) of cerebral IgG
distribution in animals fed control and 80, 000 IU VD/kg diets are shown in the last frame; IgG is shown in green and DAPI nuclei counterstaining is shown in
blue. Scale bar represents 100μm.
doi:10.1371/journal.pone.0125504.g001
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Fig 2. Blood biochemistry analyses. Blood biomarkers were measured in wild-type rats and mice
supplemented with different doses of dietary vitamin D (VD) to assess calcemic status. Blood Ionised Calcium
(B), serum Total Calcium (C) and Serum Phosphate were measured using either an iSTAT point-of-care
analyser or commercially available colorimetric kits. Data is shown asmean ± SEM. Statistical significance is
denoted by different letters (p<0.05; n = 8; one-way ANOVA followed by Tukey’s post hoc test).
doi:10.1371/journal.pone.0125504.g002
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association between iCa and capillary integrity indicated in the vitamin D studies is causal. Pro-
vision of PTH had markedly increased serum iCa to a comparable degree as dietary vitamin D
supplementation, however, PTH treated rats did not demonstrate compromised capillary per-
meability. Consistent with the findings in PTH treatment of rats, parathyroidectomy-induced
disturbances in capillary function also did not support an association of serum iCa with
Fig 3. Duration-of-treatment effects of exogenous vitamin D on calcemic status. The duration-of-treatment effects of dietary vitamin D on blood ionised
calcium, serum total calcium and serum phosphate in either control animals (open square/dotted lines) or animals fed 80, 000 IU vitamin D/kg (black circles/
solid lines) at 6, 12 and 24 weeks of age are shown. Column (A) represents data derived from Sprague-Dawley rats and column (B) of C57BL/6J mice.
p<0.05 for duration effects within each group is represented by different letters (n = 8; one-way ANOVA). * p<0.05 compared to relevant control at each
corresponding time point (dietary effects; n = 8; one-way ANOVA). Data is shown as mean ± SEM.
doi:10.1371/journal.pone.0125504.g003
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increased capillary permeability. Rather, iCa, total Ca, PTH and cerebral capillary integrity were
negatively correlated (or showed no correlation) with parenchymal abundance of IgG. Across all
experimental treatment groups, the consistent finding was a negative effect of vitamin D and a
positive effect of PTH on capillary integrity.
Capillary dysfunction characterized by inappropriate extravasation of plasma proteins is
postulated to contribute to neurovascular inflammation. Parenchymal abundance of GFAP
within CTX and HPF was used as a marker of astroglial activation. Fig 6, demonstrates a mod-
est level of heightened GFAP in rats and mice treated with a supplementary vitamin D regimen
that had resulted in increased capillary permeability. In this study, the distribution of
Fig 4. Measures of Parathyroid Hormone (PTH) in vitamin D-supplemented rats. After 12 weeks of
intervention, circulating serum concentrations of intact parathyroid hormone (PTH) were determined via
commercially available ELISA kits in each of the dietary vitamin D (VD) groups. Data shown as mean ± SEM
is indicated in the top graph. Different letters denote statistical significance between groups (p<0.05; n = 8;
one-way ANOVA followed by Tukey’s post hoc analysis). Duration-of-treatment effects in each
representative group are shown in the bottom frame for either 6, 12 or 24 weeks (control, shown as open
squares/dotted line or 80,000IU VD/kg, shown as black circles/solid black line). Different letters are indicative
of p<0.05 for duration effects within each group (n = 8; one-way ANOVA) whereas * show p<0.05 compared
to respective controls (n = 8; one-way ANOVA). All data is shown as mean ± SEM.
doi:10.1371/journal.pone.0125504.g004
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Fig 5. Parathyroidectomy and infusion of Parathyroid Hormone (PTH) studies. Cerebral parenchymal abundance of IgG in the cerebral cortex and
hippocampal formation of Sprague-Dawley rats subjected to ablation of parathyroid tissue (PTX) or exogenous infusion of parathyroid hormone (PTH) and
their respective controls at either 6, 12 or 24 weeks are shown in graphs A and B. Blood ionised calcium (C), serum total calcium (D), serum phosphate (E)
and serum intact PTH (F) were also analysed in each intervention group. Different letters denote statistical significance between groups (p<0.05; n = 4–10;
one-way ANOVA followed by Tukey’s post hoc analysis). The data shown are mean ± SEM.
doi:10.1371/journal.pone.0125504.g005
Vitamin D Modulation of Cerebral Capillary Function
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parenchymal abundance of IgG was frequently but not consistently associated with GFAP
abundance. There was no evidence of an association between parenchymal GFAP with serum
levels of iCa, total Ca, serum PTH or with vitamin D treatment per se. Rather, the provision of
exogenous PTH to otherwise normal rats was found associated with mild suppression of GFAP
activity at 12 weeks in both CTX and HP and conversely, a slight increase in GFAP activity was
reported in parathyroidectomized animals.
Discussion
Increasing evidence suggests that disturbances in blood-brain barrier integrity may increase
risk for vascular-based neurodegenerative conditions such as vascular dementia and Alzhei-
mer’s disease. The main objective of this study was to investigate putative regulatory and inte-
grative effects of exogenous vitamin D3, calcium and parathyroid hormone on the function of
cerebral capillary endothelium and neurovascular inflammation.
Parenchymal abundance of plasma derived IgG was utilized as a surrogate marker of blood-
to-brain capillary permeability. Within both the hippocampal formation and cortex of wild-
type rats and mice, the findings demonstrate that provision of exogenous dietary vitamin D
can significantly compromise the barrier properties of cerebral capillary vessels. Rats appeared
to have been more susceptible to the effects of exogenous vitamin D as significant differences
compared to control animals were realised within 6 weeks of commencement of the diet,
whereas the effect was not realized in mice until 12 weeks of intervention. Furthermore, whilst
Table 2. Correlation Table of Cerebral Capillary Permeability with markers of Vitamin D-Calcium-Parathyroid hormone homeostasis.
Animals Intervention Region of Interest Vitamin D Total Calcium Ionised Calcium Parathyroid Hormone Phosphate
Rats Vitamin D 6 weeks CTX 0.887** 0.063 0.613** -0.62** 0.163
HPF 0.803** 0.253 0.679** -0.68* 0.005
Vitamin D 12 weeks CTX 0.851** 0.619** 0.775** -0.61** -0.172
HPF 0.666** 0.529** 0.567** -0.543** -0.213
Vitamin D 24 weeks CTX 0.728** -0.337 0.448 -0.662** -0.106
HPF 0.534* -0.174 0.363 -0.349 -0.173
Mice Vitamin D 6 weeks CTX 0.300 0.172 0.145 - -0.164
HPF -0.191 -0.127 -0.116 - 0.002
Vitamin D 12 weeks CTX 0.768** 0.609** 0.730** - -0.291
HPF 0.692** 0.513** 0.613** - -0.175
Vitamin D 24 weeks CTX 0.919** 0.565 0.884** - -0.106
HPF 0.679* 0.715* 0.765** - 0.006
Rats PTX 12 weeks CTX - -0.458 -0.605 -0.608* 0.475
HPF - -0.722* -0.502 -0.079 0.726*
PTX 24 weeks CTX - -0.366 -0.629* -0.228 0.482
HPF - -0.674* -0.099 -0.48 0.325
Rats PTH Infusion 6 weeks CTX - -0.182 -0.573 - 0.001
HPF - -0.051 0.401 - -0.02
PTH Infusion 12 weeks CTX - -0.212 -0.127 - -0.228
HPF - 0.208 0.014 - 0.026
Correlation coefficients of cerebral capillary permeability (IgG) in both cerebral cortex (CTX) and hippocampal formation (HPF) with vitamin D, blood
ionised calcium, serum total calcium, parathyroid hormone and serum phosphate for all vitamin D supplemented experimental groups (rats and mice),
parathyroid gland ablated (PTX) and parathyroid hormone-infused (PTH-infusion) groups are represented in this table. (**p<0.01; *p<0.05; n = 4–10;
Pearson’s analysis).
doi:10.1371/journal.pone.0125504.t002
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Fig 6. Measure of Neuroinflammation. Neuroinflammation was assessed by measuring the voxel intensity of cerebral glial fibrillary acidic protein (GFAP)
expression in cerebral cortex (A) and hippocampal formation (B) in Sprague-Dawley rats and C57BL/6J mice fed 80,000 IU vitamin D (VD) per kilogram of
diet and their respective controls, expressed as voxels per volume unit. Cerebral GFAP expression in cortex (C) and hippocampal formation (D) in
parathyroid gland ablated (PTX) rats and parathyroid hormone (PTH) infused rats with their controls are also shown. Statistical difference represented by
different letters (p<0.05; n = 4–10; one way ANOVA followed by Tukey’s post hoc test). Data is shown as mean ± SEM. Representative 2-dimensional
immunofluorescent micrographs of neuroinflammatory GFAP, in extended focus, are shown in the last frame. Each intervention (vitamin D enrichment; PTX;
PTH-infusion) and their respective controls are indicated. GFAP is shown in yellow and nuclei in blue. Scale bar indicates 100μm.
doi:10.1371/journal.pone.0125504.g006
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the concentration of vitamin D incorporated into the diets was equivalent for the two species
studied, lower rates of feed consumption relative to body weight, resulted in rats receiving a
comparatively lower dose of exogenous vitamin D for each respective treatment arm (Table 1).
In both species, the effects of exogenous vitamin D supplementation on parenchymal abun-
dance of IgG were fully realized within 12 weeks of feeding. Thereafter, steady-state levels of
parenchymal IgG were indicated within 24 weeks of treatment, suggesting that efflux of paren-
chymal IgG via either CSF exchange or degradation within epithelial cells of the choroid plexus,
may be compensating for blood-to-brain extravasation of some plasma proteins
and macromolecules.
Regulation of capillary function or permeability by vitamin D or its bioactive metabolites
has not been previously reported, however several lines of evidence suggest the possibility of di-
rect effects on endothelial function. The vitamin D receptor is widely distributed including on
vascular endothelial cells, smooth muscle cells, microglia and cerebral neurons [47–50]. It has
been demonstrated that 1,25(OH)D3 and its precursor 25(OH)D3 both directly increase endo-
thelial mediated conversion of vitamin D to the potent metabolite, 1,25(OH)2D3, by stimulat-
ing l-alpha-hydroxylase activity. In rat and human brain endothelial cell cultures, 1,25(OH)2D3
was reported to increase p-glycoprotein expression and activity [51]. Increased blood-to-brain
kinetics of IgG could occur as a consequence of upregulated p-glycoprotein pathway, although
this would seem unlikely as it’s considered to be relatively specific. Other potential mechanisms
of increased blood-to-brain trans-capillary transport that might be influenced by vitamin D
metabolites include modulation of tight junction proteins or adherin expression, or non-
specific transcytotic mechanisms. Gascon-Barre and Huet (1983) reported that vitamin D de-
livery to brain parenchyme is principally free circulating 1,25(OH)2D via high affinity binding
sites and not associated with plasma levels of 1,25(OH)D per se [52]. If this was the case, then
sub-endothelial bioactive metabolites may also influence capillary permeability by modulating
pericyte and astrocyte function. However, these alternate regulatory pathways of trans-
endothelial transport are yet to be experimentally investigated.
The dose range of exogenous vitamin D3 provided to rats and mice in this study was within,
or considerably greater than what is ordinarily indicated for clinical therapeutic use due to
greater tolerance of vitamin D reported in rodents (Table 1) [53, 54]. Studies suggest that be-
cause of differences in l-alpha-hydroxylase activity and in the concentration of chaperone
binding proteins, comparably greater amounts of exogenous vitamin D are required to signifi-
cantly increase serum levels of bioactive vitamin D metabolites [54, 55]. Indeed, clinical studies
also demonstrate significant heterogeneity between individuals in serum active vitamin D me-
tabolites with dietary supplementation doses ranging between 1,000 IU to 20, 000 IU VD to in-
crease vitamin D and/or calcium status [56, 57].
Many studies suggest that physiological and toxicological effects of vitamin D are mediated
as a consequence of altered cellular loading with iCa. Intracellular iCa is ordinarily orders of
magnitude less than in serum, but is generally positively associated with the extracellular iCa
concentration. In this study, baseline levels of serum iCa in rats and mice was markedly differ-
ent, with significantly lower levels in mice maintained on control diets. Provision of dietary vi-
tamin D indicated a dose effect on serum iCa and total Ca, particularly in mice. Similar effects
were seen in rats, but the effect was only realized at the higher concentrations of exogenous vi-
tamin D provided. Consistent with the iCa and total Ca data, serum phosphate was reduced in
mice with increasing provision of vitamin D, but showed little effect in rats. The relatively weak
effects of exogenous vitamin D on iCa is consistent with the species differences indicated and is
comparable to the variability reported in humans.
Differences in iCa (rats and mice) and total Ca (mice) compared to control treatment
groups were realised within six weeks of commencement of vitamin D intervention and
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remained relatively constant for up to 24 weeks of feeding. Tai et al reported that acute (15 min
changes) in serum calcium did not alter integrity of the BBB indicated by permeability of radio-
labelled sucrose, however potential capillary effects with chronically raised serum iCa have not
been reported [30]. Clinical studies have however shown a correlation between serum iCa and
CSF/serum albumin ratio consistent with direct positive effects on capillary permeability [58].
However, for the latter study caution must be exercised as these subjects had primary hyper-
parathyroidism. In kidneys, elevated PTH stimulates conversion of calcidiol to the active me-
tabolite (1,25(OH)2D3). In cell culture studies, direct but paradoxical effects of iCa on
endothelial function were demonstrated by Rezic-Muzinic et al who showed the transforma-
tion of endothelial cells to a pro-inflammatory phenotype with both sub-optimal and exagger-
ated exposure to iCa [59]. Parenchymal iCa mediated effects of endothelium, endothelial
regulator cells (pericytes/astrocytes) and inflammatory cells (glia) cannot be ruled out. Howev-
er, in rodent studies maintained on supraphysiological doses of vitamin D, Murphy et al re-
ported that rats had similar levels of CSF and brain extracellular iCa to control rats [31]. The
study by Murphy et al suggested that diffusion is the primary modality of trans-endothelial
transport of iCa [31]. However, significant regional differences in 45Ca uptake into the CNS
have also been reported. The frontal cortex primarily reflects transport across cerebral capillary
endothelium, whereas uptake into ventricular CSF reflects transport across the choroid plexus-
es [30].
In vitamin D supplemented rats and mice, CTX and HPF abundance of IgG was strongly
and consistently associated with elevated serum iCa consistent with a causal association. How-
ever, this interpretation of the findings was not supported in rats infused with PTH 1–34,
where substantial increases in iCa were realized without increased abundance of parenchymal
IgG. Similarly, rats with surgical ablation of PTH tissue showed mild increased of IgG expres-
sion within CTX and HPF, concomitant with a reduction in iCa. Although it cannot be exclud-
ed from these findings, it is unlikely iCa is the primary causative factor in breakdown of
capillary endothelium but rather may exacerbate cellular dysfunctioning through promotion of
neurotoxic signalling cascades.
A strong negative correlation between capillary permeability and serum levels of PTH was
reported in vitamin D supplemented animals and it has been indicated that a causal effect is
unlikely to be via regulation of iCa. Whilst it is tempting to suggest the mechanisms may be di-
rect given the substantial ingestion of dietary-derived vitamin D, lower levels of the free active
metabolites of vitamin D as a consequence of profound PTH suppression also cannot
be excluded.
Direct effects of PTH on capillary function are not reported. However, cell culture studies
suggest that epithelial cells possess abundant PTH-receptor 1 and that PTH stimulates vascular
endothelial growth factor (VEGF-165), a critical modulator of endothelial cell proliferation
[60, 61]. PTH alters the ceramide/sphingosine-1-phosphate rheostat; potentially a key modula-
tor of endothelial function and PTH promotes endothelial nitric-oxide production, a potent va-
sodilator [61, 62]. Whilst these studies suggest that PTH generally promotes vascular integrity,
other reports suggest detrimental physiological effects of exaggerated PTH [34]. However, the
latter is indicated only if overloading of cellular iCa is occurring. In this study, infusion of
exogenous PTH 1–34 fragment to intact rats maintained on standard chow containing 1,000
IU of vitamin D per kg, increased the serum concentration of iCa to a level comparable to rats
maintained on 120, 000 IU vitamin D/kg, but without detrimental effects on cerebral capillary
permeability. Therefore, the findings do not support the notion that in this species, hyperpara-
thyroidism directly compromises capillary integrity.
Collectively, capillary permeability appears to be increased in rats and mice maintained on a
regimen of vitamin D that is likely to increase active metabolites of vitamin D and suppress
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PTH synthesis and secretion. The effects appear to plateau, suggesting chronic homeostatic ef-
fects. Parenchymal abundance of IgG is used as a surrogate marker of non-specific blood-to-
brain protein kinetics, hence presumably inappropriate delivery of other plasma proteins and
possibly macromolecules may be occurring. Many studies support the contention that persis-
tent and exaggerated parenchymal abundance of serum derived neurotoxic substances could
induce neurovascular inflammation and promote progression of several neurodegenerative dis-
orders. However, in this study, the abundance of GFAP within CTX or HPF was found not to
markedly differ in rodent treatment groups of exogenous vitamin D, PTX or PTH treated ani-
mals compared to controls. Irrespective of mechanisms, in the rodent species studied the re-
sults do not suggest that exaggerated provision of diets enriched in vitamin D significantly
promote neurovascular inflammation. However, equally the study design does not investigate
if vitamin D per se will attenuate neurovascular inflammation. Previous studies report in-
creased capillary permeability induced by diets enriched in pro-atherogenic lipids and substan-
tial neurovascular inflammation [40, 63, 64]. Clearly, it is a reasonable proposition that
excessive vitamin D could have synergistic effects with other nutrients that compromise cere-
bral capillary integrity. The latter proposition may intuitively seem unlikely given the substan-
tial body of evidence that links low levels of vitamin D with heightened inflammation.
However, provision of vitamin D above physiological levels should not be assumed to be bene-
ficial. Indeed, in a cross-sectional study completed as part of a longitudinal clinical study of
late-life depression, vitamin D consumption was found to be positively associated with brain le-
sions in elderly subjects even after controlling for potentially explanatory variables [65]
Conclusion
The findings from this study reiterate the substantial limitations when considering putative as-
sociations of between serum vitamin D, calcium and parathyroid hormone with physiological,
pathological or cognitive sequelae. A recent meta-analysis that concluded vitamin D deficiency
is associated with a substantially increased risk of all-cause dementia and Alzheimer disease,
did not take into consideration an endocrine axis of effects [17]. This study suggests that provi-
sion of exogenous vitamin D at levels that suppress PTH secretion and increase iCa concentra-
tion compromise the permeability of cerebral capillary vessels but do not promote
neurovascular inflammation per se. Potential synergistic effects of vitamin D in heightened in-
flammatory states should be investigated to further support the putative efficacy of vitamin
D supplementation.
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